Bookmark
Forward
QuickView for levetiracetam (compound)
DrugBank
Identification
| Name: | etiracetam, S-isomer |
|---|---|
| Name (isomeric): | DB01202 |
| Drug Type: | small molecule |
| Synonyms: |
Levetiracetamum [INN-Latin]; Levitiracetam; Levetiracetam [INN]
|
| Brand: | Keppra |
| Category: | Nootropic Agents, Anticonvulsants |
| CAS number: | 102767-28-2 |
Pharmacology
| Indication: | Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. |
|---|---|
| Mechanism of Action: |
The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only mi...
show more » |
| Absorption: | Rapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects. |
| Protein binding: | Very low (<10%) |
| Biotransformation: | The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. No CYP450 metabolism detected. |
| Route of elimination: | Sixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites have no known pharmacological activity and are renally excreted. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. |
| Half Life: | 6-8 hours |
| Clearance: | 0.96 mL/min/kg |
| Toxicity: | Side effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||
|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Transporters
